Tumor News and Research

RSS

Elusive stem cells offer clues to treat lumbar spinal stenosis

Researchers at Weill Cornell Medicine and Hospital for Special Surgery have discovered the stem cells—unspecialized cells that can develop into specific cell types—that give rise to the body's tendons and ligaments, the tissues connecting muscles and bones.

7 Sep 2026

Psilocybin protects sensory nerves from chemotherapy damage in preclinical study

In mouse models, prophylactic psilocybin prevented or reduced multiple features of chemotherapy-induced peripheral neuropathy, with cycle-matched dosing sustaining protection during repeated cisplatin exposure without measurably affecting tumor growth. Experiments in human-derived sensory neurons and ex vivo peripheral nerves linked the effect to 5-HT2A-dependent preservation of mitochondrial trafficking and local axonal energy supply, while a nonhallucinogenic 5-HT2A agonist reproduced protection against mechanical hypersensitivity.

6 Sep 2026

Tumor environments sculpt diverse natural killer cells for cancer therapies

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

4 Sep 2026

What your gut microbes may have to do with how your brain ages

This review examines how diet-driven changes in the gut microbiota and microbial metabolites may influence cognitive aging through immune, metabolic, neural, endocrine, and barrier-related pathways. It highlights SCFAs, tryptophan-derived metabolites, and bile acids as key signaling mediators while emphasizing that much of the mechanistic evidence remains preclinical and human evidence is largely associative.

3 Sep 2026

The four-day week has plenty of fans. Now researchers are testing what it really changes

The Sussex 4-Day Week study is a 14-week UK protocol designed to investigate how reduced working hours affect physical and mental health, wellbeing, sleep, work performance, and potential biological and psychological mechanisms. Researchers aim to combine questionnaires with actigraphy, inflammatory biomarkers, interoception testing, and brain imaging in at least 150 adults, with data collection expected to continue until 2027.

3 Sep 2026

Cancer-fighting T cells need small amounts of ROS to attack tumors, study finds

New research reveals a promising new target for treating cancer by harnessing a type of molecule previously thought to do more harm than good.

3 Sep 2026

Mount Sinai researchers discover new radiation option for childhood brain cancer

Children with one of the deadliest forms of brain cancer may benefit from an additional course of radiation therapy after their disease returns, according to new research from the Icahn School of Medicine at Mount Sinai.

2 Sep 2026

New drug class shows major promise for shrinking nerve tumors

A scientist at Cincinnati Children's who has hunted for decades for ways to shrink the painful and disfiguring nerve tumors caused by neurofibromatosis type 1 (NF1) has made a new breakthrough in the quest.

2 Sep 2026

Plant-based fats improve long-term survival for prostate cancer patients

Men diagnosed with nonmetastatic prostate cancer can generally expect to live for many years after their diagnosis. However, cardiovascular disease and other cancers remain important threats to their long-term health.

2 Sep 2026

Healthy ageing shaped by more varied biology than previously thought

Molecular changes of ageing are far more unique than previously thought, meaning two healthy individuals of identical age can experience significantly different ageing journeys.

2 Sep 2026

Researchers identify a previously unknown mechanism that can drive cancer cachexia

Researchers at Helmholtz Munich, the Heidelberg Faculty of Medicine at Heidelberg University, the German Center for Diabetes Research (DZD) and the Technical University of Munich (TUM), have identified a previously unknown mechanism that can drive cancer cachexia – a wasting process in the body that primarily affects muscle and fat tissue.

1 Sep 2026

UNC researcher wins major grant to study the role of endoplasmic reticulum in T-cell metabolism

Jessica Thaxton, PhD, MsCR, associate professor in the Department of Cell Biology and Physiology at the UNC School of Medicine and co-leader of the Cancer Cell Biology Research Program at UNC Lineberger Comprehensive Cancer Center, has been awarded a prestigious $700,000 grant from the Mathers Foundation to support research into the role of the endoplasmic reticulum in T-cell metabolism and cancer development.

1 Sep 2026

Penn Medicine tests FLASH proton therapy for cancer patients

A new form of proton therapy-designed to deliver cancer-killing radiation therapy in less than a second, through fewer total sessions, with potentially less risk of damaging side effects-is now being tested in a Phase I clinical trial at the Abramson Cancer Center of the University of Pennsylvania.

1 Sep 2026

Study reveals how melanoma weakens skin cell immune defenses

Cancers actively remodel their surrounding cells and tissues to create a microenvironment that favors their growth, survival, and spread.

1 Sep 2026

Immunotherapy shows potential for treating rising gynecological tumors

Gynecological tumors, including cervical cancer (CC), endometrial cancer (EC), and ovarian cancer (OC), represent a significant global health burden for women.

1 Sep 2026

AI tools map tumor architecture to predict treatment response

Spatial transcriptomics is a powerful tool to create a detailed map of not just how genes are expressed in a piece of tissue, but also where genetic activity takes place in different cells and locations within the tissue.

31 Aug 2026

New dual-drug strategy blocks triple-negative breast cancer growth

Triple-negative breast cancer (TNBC) has a frustrating ability to adapt. Although this aggressive form of breast cancer can initially respond well to chemotherapy, cancer cells often find ways to survive, allowing the disease to return and become resistant to treatment.

31 Aug 2026

Protein build-up may shape cancer drug response

The way cancer-causing proteins accumulate in tumors may influence how effectively a promising new generation of medicines can remove them, a study suggests.

31 Aug 2026

The scale told a similar story across three diets. The liver told a different one

In a randomized controlled trial of people with metabolically unhealthy obesity, approximately 10% weight loss improved insulin sensitivity and several cardiometabolic measures across ketogenic, Mediterranean, and very-low-fat plant-forward diets. However, the very-low-carbohydrate ketogenic diet produced larger improvements in hepatic insulin sensitivity and greater reductions in liver fat and several glucose and insulin measures than the higher-carbohydrate diets.

31 Aug 2026

FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber

The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

From Dana-Farber Cancer Institute, Inc. 29 Aug 2026